| Literature DB >> 25469152 |
Yasue Uchida1, Saiko Sugiura2, Hiromi Ueda3, Tsutomu Nakashima4, Fujiko Ando5, Hiroshi Shimokata6.
Abstract
BACKGROUND: Aging process is accompanied by a chronic sub-clinical systemic inflammation. This study aimed to assess the association between hearing impairment and polymorphisms of genes encoding cytokines deeply-committed to the inflammatory response and immune homeostasis in an elderly Japanese population. Data were collected in the Longitudinal Study of Aging surveyed biennially between 1997 and 2010. The participants without any missing information at baseline were 1,957 individuals, and the gross accumulated number of 8,675 subjects (40-89 years of age) was analyzed. Two hearing impairment criteria were taken as the better ear pure-tone average (PTABE) greater than 25 dB and greater than 40 dB. We analyzed cumulative data using generalized estimating equations to investigate the effect of 9 polymorphisms, namely, tumor necrosis factor (TNF) α, rs1800630; TNF receptor super family (TNFRSF) 1B, rs1061624; interleukin (IL)-1A, rs1800587; IL-1B, rs16944; IL-4R, rs1801275; IL-6, rs1800796; IL-10, rs1800872; IL-1 receptor-associated kinase 1 (IRAK1), rs1059702; C reactive protein (CRP), rs1130864.Entities:
Keywords: Age-related hearing loss; Longitudinal study; Polymorphism; TNFα
Year: 2014 PMID: 25469152 PMCID: PMC4252019 DOI: 10.1186/s12979-014-0018-4
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Demographics of study subjects
|
|
| |
|---|---|---|
| Number | 1957 | 8675 |
| Sex, % male | 50.4 | 51.5 |
| Mean age (SD), year | 59.2 (10.9) | 62.0 (10.4) |
| Average hearing threshold for frequencies 0.5,1, 2, 4 kHz for the better ear (SD), dB | 17.3 (12.0) | 19.7 (12.1) |
| Hearing impairment with the WHO criteria, % | 20.1 | 25.0 |
| Ear disease history, % | 27.4 | 30.2 |
| Occupational noise exposure, % | 22.8 | 21.4 |
| Hypertension, % | 24.9 | 29.6 |
| Diabetes, % | 7.5 | 8.2 |
| Dyslipidemia, % | 16.7 | 19.7 |
| Stroke, % | 2.6 | 3.8 |
| Cardiac disease, % | 11.8 | 13.4 |
| Smoking, % | 44.2 | 43.2 |
Allelic and genotypic distribution of subjects for the present analyses at baseline
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Tumor necrosis factor-α (TNF-α) | rs1800630 | A (C) | C | A | CC | CA | AA |
| 3229 (82.5) | 685 (17.5) | 1420 (72.5) | 389 (19.9) | 148 (7.6) | |||
| Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) | rs1061624 | A (G) | G | A | GG | GA | AA |
| 1916 (49.0) | 1998 (51.0) | 473 (24.2) | 970 (49.6) | 514 (26.2) | |||
| Interleukin-1A (IL1A) | rs1800587 | T (C) | C | T | CC | CT | TT |
| 3525 (90.1) | 389 (9.9) | 1587 (81.1) | 351 (17.9) | 19 (1.0) | |||
| Interleukin-1B (IL1B) | rs16944 | T (C) | C | T | CC | CT | TT |
| 2094 (53.5) | 1820 (46.5) | 546 (27.9) | 1002 (51.2) | 409 (20.9) | |||
| Interleukin 4 receptor (IL-4R) | rs1801275 | G (A) | A | G | AA | AG | GG |
| 3375 (86.2) | 539 (13.8) | 1454 (74.3) | 467 (23.9) | 36 (1.8) | |||
| Interleukin-6 (IL-6) | rs1800796 | G (C) | C | G | CC | CG | GG |
| 2969 (75.9) | 945 (24.1) | 1134 (58.0) | 701 (35.8) | 122 (6.2) | |||
| Interleukin-10 (IL-10) | rs1800872 | C (A) | A | C | AA | AC | CC |
| 2648 (67.7) | 1266 (32.3) | 896 (45.8) | 856 (43.7) | 205 (10.5) | |||
| Interleukin 1 receptor-associated kinase-1 (IRAK-1) | rs1059702 | C (T) | T | C | TT | TC | CC |
| 3000 (76.6) | 914 (23.4) | 1312 (67.0) | 376 (19.2) | 269 (13.8) | |||
| C-reactive protein 2 (CRP2) | rs1130864 | T (C) | C | T | CC | CT | TT |
| 3670 (93.8) | 244 (6.2) | 1721 (87.9) | 228 (11.7) | 8 (0.4) |
1)Reference alleles are indicated in parentheses.
Hearing impairment risk of inflammatory mediators related SNPs analyzed using logistic regression with generalized estimating equations
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
|
| rs1800630 | |||||||||
| Hearing impairment criteria | ||||||||||
| PTABE 1)>25 dB | 1.120 | 0.979-1.281 | 0.100 | 1.192 | 1.020-1.392 | 0.027 | 1.172 | 1.005-1.367 | 0.044 | |
| PTABE 40 dB | 1.090 | 0.885-1.344 | 0.417 | 1.109 | 0.884-1.390 | 0.372 | 1.106 | 0.884-1.384 | 0.380 | |
|
| rs1061624 | |||||||||
| PTABE >25 dB | 1.151 | 1.021-1.297 | 0.022 | 1.210 | 1.052-1.393 | 0.008 | 1.211 | 1.053-1.392 | 0.007 | |
| PTABE >40 dB | 1.272 | 1.052-1.538 | 0.013 | 1.293 | 1.045-1.599 | 0.018 | 1.275 | 1.026-1.584 | 0.028 | |
|
| rs1800587 | |||||||||
| PTABE >25 dB | 1.093 | 0.894-1.335 | 0.386 | 1.061 | 0.845-1.331 | 0.611 | 1.070 | 0.855-1.339 | 0.557 | |
| PTABE >40 dB | 0.975 | 0.692-1.373 | 0.885 | 0.946 | 0.660-1.354 | 0.760 | 0.956 | 0.667-1.371 | 0.807 | |
|
| rs16944 | |||||||||
| PTABE >25 dB | 0.941 | 0.834-1.060 | 0.316 | 0.915 | 0.796-1.052 | 0.212 | 0.920 | 0.801-1.057 | 0.238 | |
| PTABE >40 dB | 0.924 | 0.762-1.121 | 0.422 | 0.960 | 0.774-1.190 | 0.706 | 0.945 | 0.760-1.174 | 0.608 | |
|
| Rrs1801275 | |||||||||
| PTABE >25 dB | 0.986 | 0.829-172 | 0.872 | 1.038 | 0.851-1.265 | 0.715 | 1.031 | 0.847-1.255 | 0.761 | |
| PTABE >40 dB | 0.968 | 0.729-1.85 | 0.822 | 1.010 | 0.746-1.367 | 0.949 | 1.050 | 0.774-1.424 | 0.756 | |
|
| rs1800796 | |||||||||
| PTABE >25 dB | 1.011 | 0.881-1.161 | 0.872 | 1.083 | 0.924-1.269 | 0.327 | 1.079 | 0.922-1.262 | 0.343 | |
| PTABE >40 dB | 1.034 | 0.829-1.289 | 0.770 | 1.042 | 0.822-1.320 | 0.734 | 1.056 | 0.833-1.339 | 0.651 | |
|
| rs1800872 | |||||||||
| PTABE >25 dB | 0.981 | 0.864-1.114 | 0.764 | 0.983 | 0.844-1.145 | 0.826 | 0.973 | 0.838-1.131 | 0.725 | |
| PTABE >40 dB | 0.887 | 0.714-1.102 | 0.280 | 0.860 | 0.572-1.101 | 0.231 | 0.834 | 0.651-1.070 | 0.153 | |
|
| rs1059702 | |||||||||
| PTABE >25 dB | 1.026 | 0.912-1.55 | 0.666 | 1.012 | 0.889-1.151 | 0.862 | 1.010 | 0.888-1.148 | 0.885 | |
| PTABE >40 dB | 0.887 | 0.718-1.097 | 0.268 | 0.8161 | 0.707-1.051 | 0.141 | 0.869 | 0.713-1.058 | 0.162 | |
|
| rs1130864 | |||||||||
| PTABE >25 dB | 0.976 | 0.758-1.257 | 0.81 | 1.099 | 0.816-1.479 | 0.535 | 1.092 | 0.817-1.461 | 0.552 | |
| PTABE >40 dB | 0.924 | 0.624-1.363 | 0.692 | 1.081 | 0.711-1.643 | 0.715 | 1.113 | 0.726-1.705 | 0.623 | |
1)PTABE : pure-tone average threshold at 0.5, 1, 2 and 4 kHz for the better ear.
Moderating variables.
model 1 : No variables.
model 2 : Age and sex.
model 3 : Any history of noise exposure, ear disease, hypertension, diabetes, dyslipidemia, stroke and cardiac disease, and lifetime smoking habit in addition to those of model 2.
PCR conditions used in genotyping the inflammatory gene variants
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Tumor necrosis factor-α (TNF-α) | rs1800630 | F1(FITC) | ATG GCC CTG TCT TCG TTA AxT G | 75/77 | 62.5 | 3 | |
| F2(Texas Red) | GGC CCT GTC TTC GTT AAx GG | ||||||
| R(Biotin) | ACA GCA ATG GGT AGG AGA ATG TC | ||||||
| Interleukin-1A (IL1A) | rs1800587 | F1(FITC) | AATAATAGTAACCAGGCAACxTC | 91/92 | 60 | 2.5 | |
| F2(Texas Red) | TAATAATAGTAACCAGGCAACxCC | ||||||
| R(Biotin) | AGTGGCTAAGTTTGGGAATGG | ||||||
| Interleukin-1B (IL1B) | rs16944 | F1(FITC) | GGTGCTGTTCTCTGCCTxGG | 50 | 60 | 1.5 | |
| F2(Texas Red) | GGTGCTGTTCTCTGCCTxAG | ||||||
| R(Biotin) | TCAGAGGCTCCTGCAATTGAC | ||||||
| Interleukin 4 receptor (IL-4R) | rs1801275 | F1(FITC) | GCC CCC ACC AGT GGC TAT xGG | 49/50 | 67.5 | 2.8 | |
| F2(Texas Red) | GGC CCC CAC CAG TGG CTA TxA G | ||||||
| R(Biotin) | CAC CCT GCT CCA CCG CAT GTA | ||||||
| Interleukin-6 (IL-6) | rs1800796 | F1(FITC) | GGC AGT TCT ACA ACA GCx CC | 43/42 | 60 | 1.5 | |
| F2(Texas Red) | GCA GTT CTA CAA CAG CxG C | ||||||
| R(Biotin) | CTG TGT TCT GGC TCT CCC TG | ||||||
| Interleukin-10 (IL-10) | rs1800872 | F1(FITC) | CAG AGA CTG GCT TCC TAC AxG A | 51/53 | 62.5 | 2.5 | |
| F2(Texas Red) | CCA GAG ACT GGC TTC CTA CAx TA | ||||||
| R(Biotin) | GCC TGG AAC ACA TCC TGT GA | ||||||
| Interleukin 1 receptor-associated kinase-1 (IRAK-1) | rs1059702 | F1(FITC) | AGGGGCCAGCAAAACGGxAA | 99 | 67.5 | 2.8 | |
| F2(Texas Red) | AGGGGCCAGCAAAACGGxGA | ||||||
| R(Biotin) | GGGACCCCACCTGATCCAGGC | ||||||
| Melting curve method | |||||||
| Gene | rs No | Primers | Sequence(5'→3') | Amplicon (bp) | Annealing temp.(°C) | Mg(mM) | Probe(5'→3') |
| Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) | rs1061624 | F | CCC TCT GAC CTG CAG GCC AAG | 61 | 65 | 2 | AGC AGA GGC AGC GAG TTG |
| R | CCA TGG CAG CAG AGG CTT TCC | ||||||
| C-reactive protein 2 (CRP2) | rs1130864 | F | GAGCTCGTTAACTATGCTGGGA | 97 | 65 | 3 | GCTGGGAAACGGTCCAAA |
| R | TTATCTCCAAGATCTGTCCAACTTG | ||||||
Genotype distribution of participants at first-wave examinations of NILS-LSA before application of exclusion criteria, and comparison with those of HapMap-JPT or another public database
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
| rs1800630 | A (C) | CC | CA | AA | |
| Our baseline subjects | 1551 (72.2) | 431 (20.0) | 167 (7.8) | NS | ||
| HapMap-JPT | (71.1) | (20.0) | (8.9) | |||
|
| rs1061624 | A (G) | GG | GA | AA | |
| Our baseline subjects | 519 (24.1) | 1070 (49.8) | 560 (26.1) | NS | ||
| HapMap-JPT | (29.4) | (48.2) | (22.4) | |||
|
| rs1800587 | T (C) | CC | CT | TT | |
| Our baseline subjects | 1745 (81.2) | 385 (17.9) | 19 (0.9) | NS | ||
| HapMap-JPT | (76.7) | (20.9) | (2.3) | |||
|
| rs16944 | T (C) | CC | CT | TT | |
| Our baseline subjects | 600 (27.9) | 1096 (51.0) | 453 (21.1) | NS | ||
| PGA-UW-FHCRC: JPT_GENO_PANEL2) | (26.3) | (50.0) | (23.7) | |||
|
| rs1801275 | G (A) | AA | AG | GG | |
| Our baseline subjects | 1585 (73.8) | 522 (24.3) | 42 (1.9) | 0.034 | ||
| HapMap-JPT | (81.4) | (18.6) | (0) | |||
|
| rs1800796 | G (C) | CC | CG | GG | |
| Our baseline subjects | 1257 (58.5) | 762 (35.5) | 130 (6.0) | 0.007 | ||
| HapMap-JPT | (75.0) | (22.7) | (2.3) | |||
|
| rs1800872 | C (A) | AA | AC | CC | |
| Our baseline subjects | 985 (45.8) | 938 (43.7) | 226 (10.5) | NS | ||
| HapMap-JPT | (44.4) | (51.1) | (4.4) | |||
|
| rs1059702 | C (T) | TT | TC | CC | |
| Our baseline subjects | 1444 (67.2) | 406 (18.9) | 299 (13.9) | NS | ||
| HapMap-JPT | (66.3) | (19.8) | (14.0) | |||
|
| rs1130864 | T (C) | CC | CT | TT | |
| Our baseline subjects | 1889 (87.9) | 251 (11.7) | 9 (0.4) | NS | ||
| HapMap-JPT | (87.2) | (11.6) | (1.2) | |||
1)Reference alleles are indicated in parentheses.
2)Variation Discovery Resource. A collaboration between the University of Washington and the Fred Hutchinson Cancer Research Center.